[{"orgOrder":0,"company":"Ache Laboratorios Farmaceuticos SA","sponsor":"McQuade Center for Strategic Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BRAZIL","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"ACH000029","moa":"Adrenergic receptor-alpha 1","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Ache Laboratorios Farmaceuticos SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center for Strategic Research and Development","highestDevelopmentStatusID":"4","companyTruncated":"Ache Laboratorios Farmaceuticos SA \/ McQuade Center for Strategic Research and Development"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Partnership","leadProduct":"Bentracimab","moa":"P2Y12 receptor","graph1":"Hematology","graph2":"Phase III","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SFJ Pharmaceuticals \/ Serb","highestDevelopmentStatusID":"10","companyTruncated":"SFJ Pharmaceuticals \/ Serb"}]

Find Clinical Drug Pipeline Developments & Deals by Huhtamaki

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Through the acquisition, SERB has acquired exclusive US rights to the ticagrelor reversal agent PB2452 (bentracimab), a novel, monoclonal antibody fragment, from SFJ. SFJ will remain responsible for the ongoing trials of bentracimab and will work with SE...

                          Product Name : PB2452

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          November 05, 2023

                          Lead Product(s) : Bentracimab

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Serb

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details :

                          Product Name : ACH000029

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          August 24, 2021

                          Lead Product(s) : ACH000029

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : McQuade Center for Strategic Research and Development

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank